Updates from The Motley Fool

Latest updates on Juno Therapeutics from Fool.com.  The Fool has written over 100 articles on Juno Therapeutics.
2016's Worst Clinical Failures

It's been a rough year for drugmakers, but late clinical-stage failures made it especially tough ...

The Unsung Heroes of CAR-T

Investors are well aware of the big names in CAR-T therapies, but these companies are working beh...

3 Biotech Stocks to Buy on Sale

Severe market beatings have removed some risk from these three clinical-stage biotech stocks.

Stock Performance

View Interactive JUNO Charts
Sponsored by

Key Data Points

Primary metrics and data points about Juno Therapeutics.
Current Price: $21.44
Prev Close: $22.12
Open: $21.90
Bid: $21.10
Ask: $21.71
Day's Range: $21.22 - $22.05
52wk Range: $17.52 - $49.72
Volume: 1,188,756
Avg Vol 1,463,386
Market Cap: $2B
P/E (ttm): -7.82
EPS (ttm): ($2.83)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Juno Therapeutics.
CAPS Rating 4 out of 5
160 Outperform
6 Underperform
CAPS All Stars
39 Outperform
2 Underperform

How do you think Juno Therapeutics will perform against the market?

You pick for Juno Therapeutics is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS

CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Hans Bishop, CEO

100% Approve

Based on 5 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Juno Therapeutics.


  • Exchange: NASDAQ